Highlights Oct 5 - Oct 11, 2026
new every Sunday
This week brought movement on both evidence and oversight: the FDA opened a path for shaping ibogaine trials, while early OCD data and a fatal psilocybin case underscored the field's benefits and risks. Scheduling disputes and state implementation also showed how regulatory details can determine access and research.
-
01
FDA Seeks Public Input on Early-Phase Clinical Trial Design and Safety for Ibogaine Drug Products
The FDA is seeking input on ibogaine trial design, dosing, care settings, and cardiac and neurologic safety monitoring.
-
02
Open-label multidose psilocybin intervention shows preliminary reductions in obsessive-compulsive disorder symptoms
A small Johns Hopkins trial found reduced OCD symptoms after two psilocybin sessions, warranting larger controlled studies.
-
03
A fatal mushroom experience, disputed suicide ruling, and the case for clear warnings about psychedelic self-harm risks
A fatal self-harm case after 14 grams of mushrooms raises difficult questions about warnings, classification, and supplier accountability.
-
04
Robert Rush challenges the DEA’s evidence and proposed Schedule I classification of five tryptamines
A legal challenge disputes the DEA's evidence for scheduling five tryptamines and details the potential costs for research.
-
05
Weekly Psychedelic Policy Briefing: DEA cannabis rescheduling stay, New Mexico psilocybin rules and Oregon funding gap
A policy briefing tracks New Mexico's psilocybin rules, Oregon's funding gap, and a DEA scheduling process under scrutiny.
-
06
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper connects drug checking, ayahuasca regulation, and toxic-drug policy within a psychedelic public-health framework.